Retention Rate Of Oxcabazepine In Young Children With Symptomatic Epilepsy

Objective:To investigate the long-term retention rate,efficacy and tolerbility of Oxcabazepine in Chinese young children with symptomatic epilepsy.Methods:Clinical features of 89 cases(male/female: 48/41) from May.2009 to June.2015 were collected. Patients with symptomatic epilepsy who received mono- or adjunctive therapy with Oxcabazepine.The initial dose was 10mg/kg/d twice everyday,3-4weeks to increased to the target dose. Oxcabazepine doses ranged between 12-53mg/kg/day(mean dose:34±8.59 mg/kg/day). Investigators recorded the antiepileptic drugs,seizure frequency, electroencephalogram and side effects in the 3,6,12,24,and 36 months.Results:A total of 89 children were enrolled in this investigation.The retention rate of Oxcabazepine in 3, 6,12,24,and 36 months were 95.5%,87.6%,75.3%,56.2%,25.8%,respectively.The reason for termination were lack of efficacy 36(54.5%),end point 10(15.2%),adverse effects 8(12.1%),seizure-free 5(7.6%),follow-up loss 3(4.5%).COX analysis reveals that the age of onset was associated with drug withdrawal.In addition, patients with 50% reduction in seizure frequency in 6,12,24,and 36 months were 56.5%,55.3%,44.7%,24.7%,and with seizure-free were 36.5%, 34.1%, 29.4%,16.5%. In this investigation,16(18.0%) patients experienced one or more side effects.The most common side effects observed were drowsiness 8(42.1%) and rash 3(15.8%),and most were mild in severity.Conclusion:Our investigation demonstrates that Oxcabazepine is safe and well tolerated in young children with symptomatic epilepsy. Whereas,for the purpose of better retention rate and therapeutic benefits,we should treat discretely depending on the complicated etiology and clinical features.